SILO PHARMA INC. - COMMON STOCK

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

18 Nov 2024 08:40:00 By Nasdaq GlobeNewswire

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

31 Oct 2024 08:35:00 By Nasdaq GlobeNewswire

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

10 Sep 2024 06:35:00 By Nasdaq GlobeNewswire

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

14 Aug 2024 14:30:00 By Nasdaq GlobeNewswire

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

07 Aug 2024 08:13:00 By Nasdaq GlobeNewswire

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

26 Jul 2024 08:20:00 By Nasdaq GlobeNewswire

Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

22 Jul 2024 16:45:00 By Nasdaq GlobeNewswire

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

19 Jul 2024 08:01:00 By Nasdaq GlobeNewswire

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

18 Jul 2024 08:25:00 By Nasdaq GlobeNewswire

Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic

16 Jul 2024 06:30:00 By Nasdaq GlobeNewswire

IBN (InvestorBrandNetwork) Coverage Initiated for Silo Pharma Inc.

30 Mar 2022 08:30:00 By Nasdaq GlobeNewswire